Efficacy of a topical combination drug containing calcipotriol hydrate and betamethasone dipropionate for psoriasis

DRUG PROFILE Calcipotriol/betamethasone dipropionate: Daivobet®/Dovobet®

10.2217/14750708.2.3.343 © 2 part of Psoriasis is a common skin condition that causes significant morbidity. Treatments can be complex and time consuming. Calcipotriol plus betamethasone dipropionate ointment (Daivobet® or Dovobet®) is a stable, convenient, once-daily topical treatment for psoriasis. Compared with its individual ingredients or tacalcitol, it has a faster speed of onset and grea...

Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris

Psoriasis is one of the most common skin diseases. The mainstay of treatment for the vast majority of patients is topical therapy. A rising first-line treatment modality for psoriasis vulgaris is the two-compound ointment containing calcipotriol 50 mug/g plus betamethasone dipropionate 0.5 mg/g (Dovobet((R)), Daivobet((R)), Taclonex((R))), which combines a vitamin D analog and a corticosteroid....

Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis.

Efficacy of an Innovative Aerosol Foam Formulation of Fixed Combination Calcipotriol plus Betamethasone Dipropionate in Patients with Psoriasis Vulgaris

BACKGROUND AND OBJECTIVE The antipsoriatic effect of an innovative aerosol foam formulation of fixed combination calcipotriol 50 μg/g (as hydrate; Cal) and betamethasone 0.5 mg/g (as dipropionate; BD) was explored in order to compare the effect with that of the first-line treatment Cal/BD ointment. METHODS This was a Phase IIa, single-centre, investigator-blinded, exploratory study, with intr...

Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): a new formulation for the treatment of psoriasis.

A new compound product containing calcipotriol 50 nanograms per gm and betamethasone dipropionate 0.5mg per gm (Dovobet, LEO Pharma) in an ointment base was recently introduced in Canada for the treatment of psoriasis. Known as Daivobet in Europe, it was introduced to the Danish Market in 2001, and approved for marketing by the European Union. This compound has been shown to be more active than...